Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Redeye Life Science Day 2025
17 slides from Expres2ion Biotech Holding Ab's conference presentation, Dec 3, 2025
Slide 1: The deadliest threat in women's health deserves a better defence
Bent U. Frandsen – CEO December 3, Redeye Life Science Day 2025 The deadliest threat in women’s health deserves a better defence Hosted by STO: EXPRS2 ExpreS2ion Biotech Holding AB Org. Nr. 559033-3729
Slide 2: Breast Cancer: The #1 Killer in Women's Health
Breast Cancer: The #1 Killer in Women’s Health Current drugs save lives but leave too many behind HER2 Expression • 2.3 million women diagnosed each year1 – the most common cancer HER2 globally receptor HER2 receptors • 685,000 annual deaths1 – the leading cause of cancer mortality in send signals w
Slide 3: Significant Market Opportunity
Significant Market Opportunity ES2B-C001 is a First-in-Class breast cancer immunotherapy, targeting the entire extracellular domain of HER2 Patient distribution by region and cancer type1 Global market size: The Breast cancer therapy 1,000,000 market is €27B globally with a projected 7% annual growt
Slide 4: Big Pharma Bets Billions on HER2 Therapies
Big Pharma Bets Billions on HER2 Therapies Multi-billion dollar M&A and licensing deals show strong demand for innovative HER2 treatments Key transactions 2009 2015 2019 2019-2021 2023 • Roche $47B acquisition of • Novartis $16B asset swap • AstraZeneca $7B acquisition of • Merck $4B acquisition of
Slide 5: The Product – A Breakthrough HER2 Immunotherapy
The Product – A Breakthrough HER2 Immunotherapy 5
Slide 6: ES2B-C001 – a First-in-Class BC Vaccine
ES2B-C001 – a First-in-Class BC Vaccine Based on technology already having clinical PoC and Phase III validation (COVID-19, >4,000 subjects) HER2 protein • VLP concept exists in approved vaccines; (all 4 extra-cellular domains, i.e. HPV vaccine against cervical cancer and polyclonal effect) HBV vacc
Slide 7: Preclinical Proof-of-Concept: Robust Immune Response & Tumour Control
Preclinical Proof-of-Concept: Robust Immune Response & Tumour Control • Broad immune response: Vaccine induced polyclonal antibodies vs. HER2 Tumour-free survival3 • Tumour growth inhibition: Vaccine induced Suppressed tumour growth broad A further advantage of ES2B-C001 over monoclonal immune antib
Slide 8: ES2B-C001 Phase I trial – Design and Progress
ES2B-C001 Phase I trial – Design and Progress *Vaccine formulation including adjuvant Trial Design Trial Progress • Who? ~27 patients with advanced HER2-positive or HER2-low breast cancer (patients who have already been through standard Patient Dosage* Doses Received Study Stage treatments) Complete
Slide 9: From First Signals to Pharma Deal
From First Signals to Pharma Deal Goal: Out-license when Phase II delivers proof — or earlier if signals are strong 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Phase I: First human data Phase II: Proof of concept in Breast Cancer Potential Phase II in Gastric Regist Phase III: Pivota
Slide 10: Big Shots, Small Waistline
Big Shots, Small Waistline 10
Slide 11: About ExpreS2ion
About ExpreS2ion From early contract research organisation (CRO) to primary focus on own pipeline assets Founding & Strategy Pipeline Projects Grants & CRO Business ES2B-C001 (HER2 Breast Cancer) Grant Initiatives - Grants fund platform development and IP, and can result in license Clinical trial ag
Slide 12: Pipeline overview
Pipeline overview Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform Target Pre-clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platform 100% Breast Cancer1 ES2B-C001/HER2-VLP ExpreS
Slide 13: Extensive Vaccine Development and Oncology Experience
Extensive Vaccine Development and Oncology Experience Executive Management Fully capable of Bent U. Frandsen CEO 30 years life science management, executing to MSc, Copenhagen Business School business development and finance experience phase II POC Dr. Max Søgaard CSO 25 years research experience Ph
Slide 14: Cash Balance & Key Drivers (1Q24 – 3Q25)
Cash Balance & Key Drivers (1Q24 – 3Q25) SEK millions 100 TO 10 Warrants • Q3 2025 cash (mSEK): 36.9 Rights AdaptVac Issue 82 • Oct 2025 TO 11 gross proceeds 80 76 Dividend Grant (mSEK): 11.8 Prepayment 69 TO 11 60 Warrants • Current runway: Q2 2026 60 58 49 • Target milestones: Phase Ia (Q2’26) & P
Slide 15: Summary (Why Invest)
Summary (Why Invest) • Large unmet medical need • Differentiated therapeutic approach • Strong preclinical proof-of-concept • Catalysts ahead from clinical progress • Significant market & revenue potential • Experienced team & partnerships • Financially prudent with cash for near-term milestones Tim
Slide 16: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 17: Q&A
Q&A NASDAQ FN: EXPRS2 Innovative vaccines for a healthier world investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — Redeye Life Science Day 2025 on 6ix